deltatrials
Completed PHASE3 NCT00131495

Study of Transdermal Testosterone Patches in Menopausal Women With Low Libido

A Randomized, Double-Blind, Placebo-controlled, Parallel-group, 52-week Study to Evaluate the Efficacy/Safety of Transdermal Patches Delivering Testosterone in Menopausal Women With Low Libido Not Receiving Estrogen Therapy

Sponsor: Warner Chilcott

Conditions Hypoactive Sexual Desire Disorder
Interventions Placebo patch Testosterone (transdermal patches)
Updated 6 times since 2017 Last updated: Apr 15, 2013 Started: Jul 31, 2004 Primary completion: Feb 28, 2006 Completion: Feb 28, 2007

Listed as NCT00131495, this PHASE3 trial focuses on Hypoactive Sexual Desire Disorder and remains completed. Sponsored by Warner Chilcott, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Warner Chilcott
Data source: Warner Chilcott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Prahran, Australia